Becton Dickinson announced plans to separate its Life Sciences unit, which includes its diagnostic solutions and biosciences segments, through a potential reverse merger transaction (RMT), sale, or spinoff. This separation, which could be valued at approximately $30 billion, aims to enhance focus, drive growth, and unlock value. The announcement aligns with earlier reports indicating the company's strategic shift. In a related development, Honeywell confirmed it will split into three companies, separating its automation and aerospace technologies businesses. This decision follows previous announcements regarding the spin-off of its advanced materials business. The aerospace headquarters will remain in Phoenix, and the restructuring is seen as a response to pressure from activist investors, aiming to create value and improve operational efficiency.
An activist investor's dream scenario has come to fruition with Honeywell's decision to break up the company. Here's how it will affect workers in Phoenix. https://t.co/Bgor50z84m
Becton Dickinson to break off biosciences, diagnostic solutions https://t.co/jlY7vVeFVN
Honeywell split to bring Phoenix a new public company. What it means to Arizona https://t.co/SPyYq4S7bH